A Sarcoidosis Clinician's Perspective of MHC Functional Elements Outside the Antigen Binding Site.
A Sarcoidosis Clinician's Perspective of MHC Functional Elements Outside the Antigen Binding Site. Hum Immunol. 2018 May 30;: Authors: Judson MA Abstract Sarcoidosis is a multisystem granulomatous disease of unknown cause. Evidence supports an integral role for interactions at the MHC binding site in the development of sarcoidosis. However, despite this evidence, there are clinical data that suggest that additional mechanisms are involved in the immunopathogenesis of this disease. This manuscript provides a brief clinical description of sarcoidosis, and a clinician's perspective of the immunopathogenesis of sarcoidosis in terms of the MHC binding site, MHC functional elements beyond the binding site, and other possible alternative mechanisms. Input from clinicians will be essential in establishing the immunologic cause of sarcoidosis as a detailed phenotypic characterization of disease will be required. PMID: 29859205 [PubMed - as supplied by publisher]
Conclusion: Peptide receptor radionuclide therapy in sarcoidosis is feasible and might be a new valuable tool in patients with otherwise treatment-refractory disease. Given the long experience with and good tolerability of PRRT, further evaluation of this new treatment option for otherwise treatment-refractory sarcoidosis in larger patient cohorts is warranted.
Conditions: Sarcoidosis; Cardiomyopathies Interventions: Diagnostic Test: 18F-FDG-PET/MRI; Diagnostic Test: 18F-GE180-PET/MRI Sponsors: St. Olavs Hospital; Norwegian University of Science and Technology; University Hospital, Essen Not yet recruiting
ConclusionsThis prospective study of neurosarcoidosis increases our understanding of the pathophysiology of the disease. A reclassification of the clinical and imaging features of the disease allows an understanding of its pathophysiology and correlation with CSF indices allows an early identification of those with a more destructive disease will help to define treatment and may thereby improve outcome.
AbstractPurpose of ReviewThe goal of this review is to provide the reader with an updated summary of the cutaneous manifestations of systemic sarcoidosis, with a particular emphasis on the predilection of sarcoidosis for scars, tattoos, and other areas of traumatized skin.Recent FindingsWhile the mechanism underlying the propensity for traumatized skin to develop sarcoidosis lesions remains unclear, several theories have been proposed including the idea that cutaneous sarcoidosis represents an exuberant, antigen-driven foreign-body response, as well as the theory that traumatized skin represents an immunocompromised distri...
ConclusionThis case sheds the light on a complex regulation of PD-L1 expression in vivo on PBMC after nivolumab arrest and triggers the question of monitoring the expression of immune checkpoint on immune cells during and after treatment with ICI.
Publication date: 2018 Source:Handbook of Clinical Neurology, Volume 155 Author(s): Bastien Joubert, Kevin Rostásy, Jérôme Honnorat Immune-mediated cerebellar ataxia (CA) comprises a group of rare diseases that are still incompletely described, and are probably underdiagnosed. Both acute and progressive progressions are possible. Different syndromes have been identified, including CA associated with anti-GAD antibodies, the cerebellar type of Hashimoto encephalopathy, primary autoimmune CA, gluten ataxia, opsoclonus-myoclonus syndrome, and paraneoplastic cerebellar degenerations. Most of these syndrome...
Chronic pulmonary aspergillosis (CPA) is a slowly progressive infection mainly caused by Aspergillus fumigatus, characterized by inflammatory destruction of lung tissue with cavitation, pleural thickening and/or fibrosis, and associated with significant respiratory and constitutional symptoms [1 –3]. CPA usually affects patients with underlying structural airway disease with air-filled cavities or bullae, such as tuberculosis (TB), non-tuberculous mycobacterial infection, chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis (ABPA), pneumothorax and sarcoid osis.
Nephrology,Volume 23, Issue 6, Page 597-600, June 2018.
Authors: James WE, Baughman R Abstract INTRODUCTION: Treatment of sarcoidosis recommendations are often based on clinical experience and expert opinion. However, there are an increasing number of studies which are providing evidence to support decisions regarding treatment. Areas Covered: Several studies have identified factors associated with increased risk for organ failure or death ("danger"). There have been several studies focused on the role of treatment to improve quality of life for the patient. Sarcoidosis treatment often follows a progression, based on response. Corticosteroids remain the initia...
Condition: Cardiac Sarcoidosis Interventions: Drug: 68Ga-DOTATATE PET/CT; Drug: 18FDG PET/CT scan; Drug: 13NH3 PET/CT scan Sponsor: Mayo Clinic Not yet recruiting